Full Press Release Details
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York.
Mr. Ho and members of the IN8bio management team will host one-on-one meetings with investors throughout the conference.
H.C. Wainwright 28th Annual Global Investment Conference Date: Monday, September 14, 2026 Time: 10:00 a.m. ET Format: Fireside Chat Presenter: William Ho, Chief Executive Officer and Co-Founder Location: Kennedy II, 4th Floor, Lotte New York Palace Hotel, New York City Webcast: Webcast Link
A live webcast of the presentation will be available through the Investors section of IN8bio’s website. A replay will be available following the event.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.